Our study found that malignant cells are the only target cells of SEMA4 signaling pathway, and the sources of SEMA4 ligands are only C1 NR4A1+ Memory B cells and C5 FKBP11+ Plasma cells, so it is speculated that C1 NR4A1+ Memory B cells and C5 FKBP11+ Plasma cells may also be able to promote the development of NPC through the SEMA4 signaling pathway, which provides a highly promising new direction for the treatment of cancer patients, and we can utilize Pepinemab, an antibody targeting SEMA4, to treat NPC patients, so SEMA4 is expected to be used as a target for NPC treatment. The gene discussed is NR4A1; the disease is nasopharyngeal carcinoma.